HCV RNA Activates APCs via TLR7/TLR8 while Virus Selectively Stimulates Macrophages Without Inducing Antiviral Responses

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Zhang, Yuwei ^a,b,c   El Far, Mohamed ^a,b   Dupuy, Franck P ^a,b,c,d   Abdel Hakeem, Mohamed S ^a,e   He, Zhong ^a,b,c   Procopio, Francesco Andrea ^a,b,c   Shi, Yu ^a,b,c   Haddad, Elias K ^a,b,c   Ancuta, Petronela ^a,b   Sekaly, Rafick Pierre ^a,b,c,f   Said, Elias A ^a,b,g  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Vaccine and Gene Therapy Institute Florida (VGTI FL)   (United States)

^d RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e CAIRO UNIVERSITY   (Egypt)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

^g SULTAN QABOOS UNIVERSITY   (Oman)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; IL1B PROTEIN, HUMAN; INTERLEUKIN 1BETA; TLR7 PROTEIN, HUMAN; TLR8 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; VIRUS RNA;

ANTIGEN PRESENTING CELL; CELL LINE; GENETICS; HEK293 CELL LINE; HEPACIVIRUS; HEPATITIS C; HUMAN; IMMUNOLOGY; MACROPHAGE; METABOLISM; VIROLOGY;

ANTIGEN-PRESENTING CELLS; CELL LINE; CHLOROQUINE; HEK293 CELLS; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERLEUKIN-1BETA; MACROPHAGES; RNA, VIRAL; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8;

EID: 84978116776     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep29447     Document Type: Article

References (55)

1. Messina, J. P. et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61, 77-87, doi: 10. 1002/hep. 27259 (2015).
2. Lavanchy, D. The global burden of hepatitis C. Liver international: official journal of the International Association for the Study of the Liver 29 Suppl 1, 74-81, doi: 10. 1111/j. 1478-3231. 2008. 01934. x (2009).
3. Seeff, L. B. The history of the natural history of hepatitis C (1968-2009). Liver international: official journal of the International Association for the Study of the Liver 29 Suppl 1, 89-99, doi: 10. 1111/j. 1478-3231. 2008. 01927. x (2009).
4. Thimme, R., Binder, M. & Bartenschlager, R. Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. FEMS microbiology reviews 36, 663-683, doi: 10. 1111/j. 1574-6976. 2011. 00319. x (2012).
5. Shin, E. C. et al. Delayed induction, not impaired recruitment, of specific CD8(+ ) T cells causes the late onset of acute hepatitis C. Gastroenterology 141, 686-695, 695 e681, doi: 10. 1053/j. gastro. 2011. 05. 006 (2011).
6. Horner, S. M. & Gale, M., Jr. Regulation of hepatic innate immunity by hepatitis C virus. Nature medicine 19, 879-888, doi: 10.1038/nm.3253 (2013).
7. Akira, S. & Takeda, K. Toll-like receptor signalling. Nature reviews. Immunology 4, 499-511, doi: 10. 1038/nri1391 (2004).
8. Wang, N. et al. Toll-like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells. Journal of virology 83, 9824-9834, doi: 10. 1128/JVI. 01125-09 (2009).
9. Lee, J. et al. TNF-alpha Induced by Hepatitis C Virus via TLR7 and TLR8 in Hepatocytes Supports Interferon Signaling via an Autocrine Mechanism. PLoS pathogens 11, e1004937, doi: 10. 1371/journal. ppat. 1004937 (2015).
10. Negash, A. A. et al. IL-1beta production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS pathogens 9, e1003330, doi: 10. 1371/journal. ppat. 1003330 (2013).
11. Uzri, D. & Gehrke, L. Nucleotide sequences and modifications that determine RIG-I/RNA binding and signaling activities. Journal of virology 83, 4174-4184, doi: 10. 1128/JVI. 02449-08 (2009).
12. Schnell, G., Loo, Y. M., Marcotrigiano, J. & Gale, M., Jr. Uridine composition of the poly-U/UC tract of HCV RNA defines non-self recognition by RIG-I. PLoS pathogens 8, e1002839, doi: 10. 1371/journal. ppat. 1002839 (2012).
13. Saito, T., Owen, D. M., Jiang, F., Marcotrigiano, J. & Gale, M., Jr. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 454, 523-527, doi: 10. 1038/nature07106 (2008).
14. Dansako, H. et al. Class A scavenger receptor 1 (MSR1) restricts hepatitis C virus replication by mediating toll-like receptor 3 recognition of viral RNAs produced in neighboring cells. PLoS pathogens 9, e1003345, doi: 10. 1371/journal. ppat. 1003345 (2013).
15. Horner, S. M. Activation and Evasion of Antiviral Innate Immunity by Hepatitis C Virus. Journal of molecular biology, doi: 10. 1016/j. jmb. 2013. 10. 032 (2013).
16. Takahashi, K. et al. Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. Proceedings of the National Academy of Sciences of the United States of America 107, 7431-7436, doi: 10. 1073/pnas. 1002301107 (2010).
17. Zhang, Y. L., Guo, Y. J., Bin, L. & Sun, S. H. Hepatitis C virus single-stranded RNA induces innate immunity via Toll-like receptor 7. Journal of hepatology 51, 29-38, doi: 10. 1016/j. jhep. 2009. 03. 012 (2009).
18. Wang, C. H. et al. TLR7 and TLR8 gene variations and susceptibility to hepatitis C virus infection. PloS one 6, e26235, doi: 10. 1371/ journal. pone. 0026235 (2011).
19. Schott, E. et al. Association of TLR7 single nucleotide polymorphisms with chronic HCV-infection and response to interferon-abased therapy. Journal of viral hepatitis 15, 71-78, doi: 10. 1111/j. 1365-2893. 2007. 00898. x (2008).
20. Schott, E. et al. A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. Journal of hepatology 47, 203-211, doi: 10. 1016/j. jhep. 2007. 03. 021 (2007).
21. Heil, F. et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303, 1526-1529, doi: 10. 1126/ science. 1093620 (2004).
22. Barrat, F. J. et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. The Journal of experimental medicine 202, 1131-1139, doi: 10. 1084/jem. 20050914 (2005).
23. Pohlmann, S. et al. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. Journal of virology 77, 4070-4080 (2003).
24. Zampino, R. et al. Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. World journal of hepatology 5, 528-540, doi: 10. 4254/wjh. v5. i10. 528 (2013).
25. Szabo, G. & Petrasek, J. Inflammasome activation and function in liver disease. Nature reviews. Gastroenterology & hepatology 12, 387-400, doi: 10. 1038/nrgastro. 2015. 94 (2015).
26. Longman, R. S., Talal, A. H., Jacobson, I. M., Albert, M. L. & Rice, C. M. Presence of functional dendritic cells in patients chronically infected with hepatitis C virus. Blood 103, 1026-1029, doi: 10. 1182/blood-2003-04-1339 (2004).
27. Rollier, C. et al. Chronic hepatitis C virus infection established and maintained in chimpanzees independent of dendritic cell impairment. Hepatology 38, 851-858, doi: 10. 1053/jhep. 2003. 50426 (2003).
28. Ludwig, I. S. et al. Hepatitis C virus targets DC-SIGN and L-SIGN to escape lysosomal degradation. Journal of virology 78, 8322-8332, doi: 10. 1128/JVI. 78. 15. 8322-8332. 2004 (2004).
29. Mengshol, J. A. et al. Impaired plasmacytoid dendritic cell maturation and differential chemotaxis in chronic hepatitis C virus: associations with antiviral treatment outcomes. Gut 58, 964-973, doi: 10. 1136/gut. 2008. 168948 (2009).
30. Sun, P. et al. Functional characterization of ex vivo blood myeloid and plasmacytoid dendritic cells after infection with dengue virus. Virology 383, 207-215, doi: 10. 1016/j. virol. 2008. 10. 022 (2009).
31. Collin, M., Bigley, V., Haniffa, M. & Hambleton, S. Human dendritic cell deficiency: the missing ID? Nature reviews. Immunology 11, 575-583, doi: 10. 1038/nri3046 (2011).
32. Gringhuis, S. I. et al. HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nature immunology 11, 419-426, doi: 10. 1038/ni. 1858 (2010).
33. Schwartz, A. J., Alvarez, X. & Lackner, A. A. Distribution and immunophenotype of DC-SIGN-expressing cells in SIV-infected and uninfected macaques. AIDS research and human retroviruses 18, 1021-1029, doi: 10. 1089/08892220260235380 (2002).
34. Lai, W. K. et al. Expression of DC-SIGN and DC-SIGNR on human sinusoidal endothelium: a role for capturing hepatitis C virus particles. The American journal of pathology 169, 200-208, doi: 10. 2353/ajpath. 2006. 051191 (2006).
35. Angel, C. E. et al. CD14+ antigen-presenting cells in human dermis are less mature than their CD1a+ counterparts. International immunology 19, 1271-1279, doi: 10. 1093/intimm/dxm096 (2007).
36. Kwon, D. S., Gregorio, G., Bitton, N., Hendrickson, W. A. & Littman, D. R. DC-SIGN-mediated internalization of HIV is required for trans-enhancement of T cell infection. Immunity 16, 135-144 (2002).
37. Raychoudhuri, A. et al. ISG56 and IFITM1 proteins inhibit hepatitis C virus replication. Journal of virology 85, 12881-12889, doi: 10. 1128/JVI. 05633-11 (2011).
38. Kwon, Y. C., Kang, J. I., Hwang, S. B. & Ahn, B. Y. The ribonuclease L-dependent antiviral roles of human 2 , 5-oligoadenylate synthetase family members against hepatitis C virus. FEBS letters 587, 156-164, doi: 10. 1016/j. febslet. 2012. 11. 010 (2013).
39. Zhao, Y., Kang, H., Ji, Y. & Chen, X. Evaluate the relationship between polymorphisms of OAS1 gene and susceptibility to chronic hepatitis C with high resolution melting analysis. Clinical and experimental medicine 13, 171-176, doi: 10. 1007/s10238-012-0193-6 (2013).
40. Kim, M. J. & Yoo, J. Y. Inhibition of hepatitis C virus replication by IFN-mediated ISGylation of HCV-NS5A. Journal of immunology 185, 4311-4318, doi: 10. 4049/jimmunol. 1000098 (2010).
41. Allen, I. C. et al. NLRX1 protein attenuates inflammatory responses to infection by interfering with the RIG-I-MAVS and TRAF6-NF-kappaB signaling pathways. Immunity 34, 854-865, doi: 10. 1016/j. immuni. 2011. 03. 026 (2011).
42. Moore, C. B. et al. NLRX1 is a regulator of mitochondrial antiviral immunity. Nature 451, 573-577, doi: 10. 1038/nature06501 (2008).
43. Schroder, K. et al. Differential effects of CpG DNA on IFN-beta induction and STAT1 activation in murine macrophages versus dendritic cells: alternatively activated STAT1 negatively regulates TLR signaling in macrophages. Journal of immunology 179, 3495-3503 (2007).
44. Kohase, M. et al. Interleukin-1 can inhibit interferon-beta synthesis and its antiviral action: comparison with tumor necrosis factor. Journal of interferon research 8, 559-570 (1988).
45. Ivashkiv, L. B. & Donlin, L. T. Regulation of type I interferon responses. Nature reviews. Immunology 14, 36-49, doi: 10. 1038/nri3581 (2014).
46. Tian, Z., Shen, X., Feng, H. & Gao, B. IL-1 beta attenuates IFN-alpha beta-induced antiviral activity and STAT1 activation in the liver: involvement of proteasome-dependent pathway. Journal of immunology 165, 3959-3965 (2000).
47. Naiki, Y. et al. TGF-beta1 inhibits the production of IFN in response to CpG DNA via ubiquitination of TNF receptor-associated factor (TRAF) 6. Innate immunity 21, 770-777, doi: 10. 1177/1753425915596844 (2015).
48. Varano, B. et al. Inhibition of the constitutive and induced IFN-beta production by IL-4 and IL-10 in murine peritoneal macrophages. Virology 277, 270-277, doi: 10. 1006/viro. 2000. 0560 (2000).
49. Polyak, S. J., Khabar, K. S., Rezeiq, M. & Gretch, D. R. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. Journal of virology 75, 6209-6211, doi: 10. 1128/JVI. 75. 13. 6209-6211. 2001 (2001).
50. Itoh, Y. et al. Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection. The American journal of gastroenterology 94, 1332-1340, doi: 10. 1111/j. 1572-0241. 1999. 01083. x (1999).
51. Jouan, L. et al. Targeted impairment of innate antiviral responses in the liver of chronic hepatitis C patients. Journal of hepatology 56, 70-77, doi: 10. 1016/j. jhep. 2011. 07. 017 (2012).
52. Said, E. A. et al. A Potential Inhibitory Profile of Liver CD68+ Cells during HCV Infection as Observed by an Increased CD80 and PD-L1 but Not CD86 Expression. PloS one 11, e0153191, doi: 10. 1371/journal. pone. 0153191 (2016).
53. Tu, Z. et al. Hepatitis C virus core protein subverts the antiviral activities of human Kupffer cells. Gastroenterology 138, 305-314, doi: 10. 1053/j. gastro. 2009. 09. 009 (2010).
54. Bergmann, J. F. et al. Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV. Alimentary pharmacology & therapeutics 34, 443-453, doi: 10. 1111/j. 1365-2036. 2011. 04745. x (2011).
55. Horsmans, Y. et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 42, 724-731, doi: 10. 1002/hep. 20839 (2005).